text: 424,173,1488434222775902210,1364749022,Haitham Bou Ammar,"Designing fast antibodies is critical in successfully countering diseases. In this paper, we collaborate with @victorgreiff team and with @DanyBouAmmar from @AUBMC_Official to propose an effective Bayesian optimisation solver: <LINK> <LINK> We show: 1. A new way to search for antibody CDRH3s using Bayesian optimisation with various kernels, including Protein Bert warps. 2. We devise a constraint acquisition maximiser that finds new CDRH3 within a trust region while being feasible w.r.t antibody development constraints. 3. We show high-affinity and super+ high-affinity binders in only 38 and 85 trials, respectively. @ImanisMind @KhanAsif__",https://arxiv.org/abs/2201.12570,"Antibodies are canonically Y-shaped multimeric proteins capable of highly specific molecular recognition. The CDRH3 region located at the tip of variable chains of an antibody dominates antigen-binding specificity. Therefore, it is a priority to design optimal antigen-specific CDRH3 regions to develop therapeutic antibodies to combat harmful pathogens. However, the combinatorial nature of CDRH3 sequence space makes it impossible to search for an optimal binding sequence exhaustively and efficiently, especially not experimentally. Here, we present AntBO: a Combinatorial Bayesian Optimisation framework enabling efficient in silico design of the CDRH3 region. Ideally, antibodies should bind to their target antigen and be free from any harmful outcomes. Therefore, we introduce the CDRH3 trust region that restricts the search to sequences with feasible developability scores. To benchmark AntBO, we use the Absolut! software suite as a black-box oracle because it can score the target specificity and affinity of designed antibodies in silico in an unconstrained fashion. The results across 188 antigens demonstrate the benefit of AntBO in designing CDRH3 regions with diverse biophysical properties. In under 200 protein designs, AntBO can suggest antibody sequences that outperform the best binding sequence drawn from 6.9 million experimentally obtained CDRH3s and a commonly used genetic algorithm baseline. Additionally, AntBO finds very-high affinity CDRH3 sequences in only 38 protein designs whilst requiring no domain knowledge. We conclude AntBO brings automated antibody design methods closer to what is practically viable for in vitro experimentation. ","AntBO: Towards Real-World Automated Antibody Design with Combinatorial